Philips launches new IntelliSpace Portal 8.0 platform for diagnosis and cancer treatment

29 November 2015 (Last Updated November 29th, 2015 18:30)

Royal Philips has launched the latest edition of its advanced data sharing, analytics and visualisation platform, IntelliSpace Portal 8.0, that helps radiologists detect, diagnose and follow-up on treatment of diseases.

Philips

Royal Philips has launched the latest edition of its advanced data sharing, analytics and visualisation platform, IntelliSpace Portal 8.0, that helps radiologists detect, diagnose and follow-up on treatment of diseases.

The platform, which was introduced at the 2015 Radiological Society of North America Annual Meeting (RSNA) in Chicago, US, helps to address changing demands in radiology that result from an increasing prevalence of cancer and its economic toll.

It also delivers new applications such as fast 3D quantitative renderings of tumours in a fully integrated oncology suite to improve diagnostic confidence and patient care.

The oncology suite complements the width and depth of applications that IntelliSpace Portal offers as a comprehensive, advanced analysis platform.

With automated and guided workflow, it enables clinicians to visualise, diagnose, measure disease states and communicate across modalities. The platform supports more than 68 clinical applications for seven modalities, including CT, MR, ultrasound, mammography and iXR.

"Radiology has a unique ability to influence and improve outcomes."

Philips healthcare informatics solutions and services CEO Jeroen Tas said: "Radiology has a unique ability to influence and improve outcomes. Today there is so much data available, but its full potential is not often realised.

"Advances in digital health technology now allow us to integrate clinical data from multiple modalities and sources and make that data meaningful and quickly accessible to radiologists."

IntelliSpace Portal 8.0 is incorporated with a new CT lung nodule assessment (LNA) application that provides effective and longitudinal workflow.

The platform also features applications that will help clinicians to measure and track COPD, detect pulmonary embolism and perform calcium scoring.

Its MR cardiac quantitative mapping provides fast quantification and analysis workflow for T1, T2, and T2 generated maps to enhance the diagnostic view in cardiomyopathies.


Image: Quantitative tumour viability (qEASL) before and after chemoembolisation (TACE). Photo: courtesy of PRNewswire / Royal Philips.